Supplementary information

Clinical and therapeutic relevance of cancer-associated fibroblasts

Supplementary Table 1 │ Widely used biomarkers of CAFs and their clinical relevance

Gene	Marker	CAF subset	Expression in other cell types	Cellular location	Prognostic value based on HPA-TCGA[a]	
					Unfavourable	**Favourable**
ACTA2	αSMA[1-9]	Peritumoural myofibroblasts	Pericytes, smooth muscle cells and breast myoepithelial cells	Intracellular	Renal cancer	–
FAP	FAP[8-15]	A subset of myofibroblasts	Pericytes, smooth muscle cells, myocytes and glandular cells	Membrane and secreted	Head and neck cancer	–
S100A4	S100A4 (FSP1)[9,16-18]	Interstitial CAFs (apCAFs and some iCAFs)	Myeloid cells, some (EMT) cancer cells, haematopoietic cells, pneumocytes and urothelial cells	Membrane	Renal cancer	Head and neck cancer
TAGLN	Transgelin[5-7,19]	Myofibroblasts	Pericytes, smooth muscle cells and breast myoepithelial cells	Intracellular	Renal cancer	–
THY1	Thy1/CD90[5,20,21]	Myofibroblasts	T cells and neurons	Membrane and nucleoplasm	Renal cancer and glioma	–
LRRC15	LRRC15[10,22,23]	A subset of myofibroblasts	Glandular cells, smooth muscle cells and myocytes	Membrane	–	–
TNC	Tenascin C[5,24-27]	Myofibroblasts	Pericytes and cancer cells	Secreted	–	–
PDGFRB	PDGFRβ[5,9,28,29]	Myofibroblasts and some αSMA-low CAFs	Pericytes and neurons	Membrane	Renal cancer and urothelial cancer	–
PDGFRA	PDGFRα[5,6,28-33]	αSMA-low CAFs and some αSMA⁺ CAFs	Breast myoepithelial cells	Membrane	Renal cancer	Head and neck cancer
CAV1	Caveolin-1[34-36]	αSMA-low CAFs	Endothelial cells, some cancer cells, pericytes, pneumocytes, squamous epithelial cells, smooth muscle cells and myocytes	Membrane	Renal cancer and lung cancer	–
CLEC3B	CLEC3B[5,37-39]	αSMA-low CAFs	Renal tubule epithelial cells	Secreted	–	Pancreatic cancer, head and neck cancer and liver cancer
VIM	Vimentin[40,41]	Pan-CAF biomarker	Some (EMT) cancer cells, endothelial cells, pneumocytes, glandular cells, adipocytes, and haematopoietic and/or lymphoid cells	Intracellular	Renal cancer	Endometrial cancer
PDPN	Podoplanin[5,8,17,42,43]	Pan-CAF biomarker	Lymphatic endothelial cells, some myeloid cells, pneumocytes and breast myoepithelial cells	Membrane	–	–
DES	Desmin[44,45]	Pan-CAF biomarker, especially myofibroblasts	Pericytes, smooth muscle cells and myocytes	Intracellular	Renal cancer	–
DCN	Decorin[46]	Pan-CAF biomarker	Some epithelial and cancer cells and adipocytes	Secreted	Renal cancer	–
DDR2	DDR2[47,48]	Pan-CAF biomarker	Pericytes, smooth muscle cells and some cancer cells	Membrane	Renal cancer	–
LOX	LOX[49]	Pan-CAF biomarker	Some cancer cells	Secreted	Liver cancer, renal cancer, urothelial cancer	–

LOXL1	LOXL1	Pan-CAF biomarker	Pericytes and cancer cells	Secreted	Glioma	–
LOXL2	LOXL2[50]	Pan-CAF biomarker	Pericytes and cancer cells	Secreted	Lung cancer, renal cancer, cervical cancer, glioma and pancreatic cancer	–
MFAP5	MFAP5[7,51,52]	Pan-CAF biomarker	Smooth muscle cells	Secreted	Stomach cancer and urothelial cancer	–
MMP2	MMP2[7]	Pan-CAF biomarker	Some cancer cells and endothelial cells	Secreted	–	–
POSTN	Periostin[53]	Pan-CAF biomarker	Pericytes, neurons, glial cells, respiratory epithelial cells and glandular cells	Secreted and nucleoplasm	Renal cancer, lung cancer, stomach cancer	–
COL3A1	COL3A1[5]	Pan-CAF biomarker	Pericytes	Secreted	Renal cancer	–
SPARC	SPARC (osteonectin)[54]	Pan-CAF biomarker	Endothelial cells, cancer cells, haematopoietic cells and glandular cells	Secreted	Renal cancer	–
FGFR1	FGFR1	Pan-CAF biomarker	Endothelial cells, cancer cells, glandular cells, smooth muscle cells and myocytes	Membrane	–	–

apCAFs, antigen-presenting cancer-associated fibroblasts; cancer-associated fibroblast; CAF, cancer-associated fibroblast; EMT, epithelial-to-mesenchymal transition; iCAFs, inflammatory cancer-associated fibroblasts. [a]The prognostic values of indicated CAF biomarkers are based on the analyses by the Human Protein Atlas (HPA) based on the datasets from The Cancer Genome Atlas (TCGA) programme. A prognostic gene was defined with a log rank $P < 0.001$ in maximally separated Kaplan–Meier analysis (based on the RNA-sequencing fragments per kilobase million (FPKM) value of a given gene). Patients were classified into two expression groups and analyzed for the correlation between gene-expression level and survival.

Supplementary Table 2 │ Therapeutic strategies targeting CAFs in cancers and related clinical trials

Agent	Target	Therapeutic category	Mechanism of action	Development status	Clinical trials
PEGPH20	Hyaluronic acid	PEGylated enzyme	Enzymatic degradation of excessive stromal hyaluronan[55]	Phase III trials halted in Nov 2019	NCT02241187 and NCT03634332
Pamrevlumab (FG-3019)	CTGF	Human monoclonal antibody	Antagonizes the action of CTGF[56]	Phase III trials	NCT01181245, NCT02210559 and NCT03941093
Simtuzumab (GS-6624)	LOXL2	Humanized monoclonal antibody	Blocks fibroblast recruitment and collagen cross-linking functions of LOXL2[57]	Phase II trial for pancreatic cancer completed in 2014. Phase II trials for IPF and colorectal cancer terminated.	NCT01472198, NCT01769196, NCT01479465 and NCT02466516
Olaratumab	PDGFRα	Human monoclonal antibody	Antagonizes PDGFRα signaling[58]	Phase I and II trials	NCT03086369, NCT03994627, NCT03802071 and NCT03985722
Cabiralizumab (BMS-986227, FPA008)	CSF1R	Humanized monoclonal antibody	Inhibits CSF1R signalling; functional suppression of monocytes and macrophages[59]	Phase I and II trials	NCT03599362, NCT03336216, NCT04050462, NCT03502330 and NCT04331067
Istiratumab (MM-141)	IGF1R and HER3 (ErbB3)	Human tetravalent bispecific antibody	Blockade of the IGF-1R and HER3 (ErbB3) pathways in pancreatic cancer cells[60]	Phase I trial terminated	NCT02538627
Xentuzumab (BI 836845) or MEDI-573	IGF1 and IGF2	Humanized monoclonal antibody	Inhibits IGF1-stimulated and IGF2-stimulated activation of IGFRs[61]	Phase I and II trials	NCT02191891, NCT02204072, NCT02123823, NCT01446159 and NCT00816361
CAR T cell product	FAP	CAR T cells targeting FAP	Depletion of FAP-expressing CAFs and immune modulation[62-64]	Preclinical studies	NA
^{131}I-sibrotuzumab	FAP	Radioactive isotope-conjugated antibody	131I-labeled FAP-targeting antibody uptake in FAP-positive tumors[65]	Phase I trial for lung cancer terminated	NCT02209727
RO6874281 (FAP-IL2v, RG7461)	FAP	Antibody moiety linked to cytokine (immunocytokine)	Binding to FAP and targeting IL-2 (IL-2v) to FAP-expressing cells/tumours[66]	Phase I–II for multiple cancer types	NCT03875079, NCT02627274, NCT03386721 and NCT03193190
ATRA	Vitamin A metabolism	Metabolite	CAF normalization and restrained tumour growth[67,68]	Phase I–II trials for multiple cancer types	NCT03307148, NCT04113863, NCT04241276, NCT03999684, NCT03200847, NCT03572387 and NCT04433169
Paricalcitol (vitamin D analogue)	Vitamin D receptor	Small-molecule agonist	CAF normalization and improved chemotherapeutic efficacy[69]	Phase I–II for multiple cancer types	NCT03883919, NCT03415854, NCT03520790, NCT04054362, NCT02930902, NCT03519308, NCT02754726 and NCT03138720

Fresolimumab (GC1008)	TGFβ	Human monoclonal antibody	Blocks TGFβ signalling[70]	Phase I/II trial for lung cancer	NCT02581787
Galunisertib (LY2157299)	TGFβ receptor I kinase	Small-molecule inhibitor	Blocking TGFβ signaling and CAF activation[71]	Phase I–II for multiple cancer types	NCT01373164, NCT02688712, NCT02452008, NCT04031872, NCT03206177 and NCT02672475
Vismodegib (GDC-0449)	Hedgehog	Small-molecule inhibitor	Inhibition of HH–SMO signalling and tumour growth inhibition. Potential deactivation of CAFs[72]	Approved for basal-cell carcinoma (phase IV studies ongoing). Phase I–II trials for multiple cancer types.	NCT03610022, NCT02667574, NCT03052478, NCT02371967 and NCT00878163
LDE225 (Sonidegib)	Hedgehog	Small-molecule inhibitor	Inhibition of SMO and HH signalling pathway[73]	Approved for basal-cell carcinoma. Phase I for multiple cancer types	NCT04007744
Saridegib or patidegib (IPI-926)	Hedgehog	Small-molecule inhibitor	Inhibition of HH–SMO signalling, stromal depletion and facilitated drug delivery[74]	Phase II trials for basal cell carcinoma, phase III for basal cell nevus syndrome (as patidegib); phase I-II trials for multiple cancer types (as IPI-926 or saridegib)	NCT01130142, NCT04155190, NCT04308395, NCT00761696, NCT01383538 and NCT01310816
TP-0903	AXL	Small-molecule inhibitor	Inhibition of AXL on cancer cells, CAFs, and myeloid cells[75]	Phase I trial for solid tumours	NCT02729298
Plerixafor (AMD3100)	CXCR4	Small-molecule inhibitor	Blocks CXCL12(SDF1)–CXCR4 interaction and immune modulation[11]	Phase II–III trials for multiple cancer types	NCT03277209, NCT04177810, NCT04058145, NCT03746080 and NCT00103662
BL-8040	CXCR4	Small-molecule inhibitor	CXCL12-CXCR4 inhibition and immune regulation[76]	Phase II–III trials for multiple cancer types	NCT02826486, NCT04543071 and NCT02907099
Defactinib (VS-6063, PF-04554878)	FAK	Small-molecule inhibitor	Restrains tumour growth through FAK inhibition[77]	Phase I–II trials for multiple cancer types	NCT04201145, NCT03875820, NCT02758587, NCT03727880, NCT03287271, NCT04331041 and NCT04439331
Erdafitinib (JNJ-42756493)	FGFR1−4	Small-molecule inhibitor	Inhibits FGFRs expressed by cancer cells and antagonizing the signalling induced by FGF released from CAFs[78,79]	Approved for urothelial and bladder cancer. Phase I–III trials for multiple cancer types	NCT04083976, NCT03473743, NCT02699606, NCT02952573, NCT04172675, NCT04330248, NCT03238196, NCT03210714, NCT03390504 and NCT03999515
BGJ398, Debio-1347, AZD4547 or TAS120	FGFR1−3	Small-molecule inhibitors	Inhibit tumour growth. Induction of CAF senescence or inactivation[80]	Phase I–III trial for multiple cancer types	NCT02150967, NCT03773302, NCT04197986, NCT04228042, NCT04233567,

					NCT03344536, NCT01824901 and NCT04024436
AT13148	AGC kinases (ROCK, AKT, PKA)	ATP-competitive small-molecule iinhibitor	Inhibition of PI3K-AKT pathway signaling through AGC kinases[81]	Phase I trial for advanced-stage solid tumours	NCT01585701
Imatinib	PDGFR, BCR–ABL1 and KIT	Tyrosine kinase inhibitor	Inhibits tumour growth and angiogenesis. PDGFR inhibition in CAFs and pericytes[82]	Approved for CML, ALL and gastrointestinal stromal tumour	NA
Dasatinib	SRC and ABL1	ATP-competitive tyrosine kinase inhibitor	Inhibits cancer cells and CAFs[83]	Approved for CML and ALL	NA
PF-04136309	CCR2	Antagonist	Blocks CCL2–CCR2 signalling	Phase I/II trial for pancreatic cancer terminated	NCT02732938
Siltuximab or tocilizumab	IL-6 and IL-6R, respectively	Chimeric and humanized monoclonal antibody, respectively	Block IL-6–IL-6R signalling[84]	Approved for Castleman disease and arthritis. Phase I–II trials for multiple cancer types	NCT04191421 and NCT04375228
Danvatirsen (AZD9150)	STAT3	Antisense oligonucleotide	Inhibits STAT3 signalling[85]	Phase II trial for multiple cancer types	NCT02983578
Andecaliximab (GS-5745)	MMP9	Recombinant chimeric IgG4 monoclonal antibody	Inhibits MMP9[86]	Phase I/II/III for multiple cancer types	NCT02545504, NCT03631836, NCT01803282 and NCT02864381
S-3304	MMPs	Small-molecule inhibitor	Inhibits MMPs and ECM degradation[87]	Phase I–II trials	NCT00033566, NCT00078390 and NCT00033215
[131]I-m81C6	Tenascin	Radioactive isotope-conjugated antibody	^{131}I-labelled tenascin-targeting antibody for distribution to tumours[88]	Phase I–II trials	NCT00002752 and NCT00003478

ALL, acute lymphocytic leukaemia; ATRA, all-trans retinoic acid; CAF, cancer-associated fibroblast; CAR, chimeric antigen receptor; CML, chronic myeloid leukaemia; ECM, extracellular matrix; MMPs, matrix metalloproteinases; NA, not applicable.

Supplementary references

1 Ronnov-Jessen, L. & Petersen, O. W. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. *Lab Invest* **68**, 696-707 (1993).

2 Ozdemir, B. C. *et al.* Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer Cell* **25**, 719-734, doi:10.1016/j.ccr.2014.04.005 (2014).

3 Ohlund, D. *et al.* Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med* **214**, 579-596, doi:10.1084/jem.20162024 (2017).

4 Biffi, G. *et al.* IL1-Induced JAK/STAT Signaling Is Antagonized by TGFbeta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. *Cancer Discov* **9**, 282-301, doi:10.1158/2159-8290.CD-18-0710 (2019).

5 Elyada, E. *et al.* Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov* **9**, 1102-1123, doi:10.1158/2159-8290.CD-19-0094 (2019).

6 Hosein, A. N. *et al.* Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. *JCI insight* **5**, doi:10.1172/jci.insight.129212 (2019).

7 Li, H. *et al.* Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. *Nature genetics* **49**, 708-718, doi:10.1038/ng.3818 (2017).

8 Puram, S. V. *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. *Cell* **171**, 1611-1624 e1624, doi:10.1016/j.cell.2017.10.044 (2017).

9 Costa, A. *et al.* Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. *Cancer Cell* **33**, 463-479 e410, doi:10.1016/j.ccell.2018.01.011 (2018).

10 Kieffer, Y. *et al.* Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. *Cancer Discov*, doi:10.1158/2159-8290.CD-19-1384 (2020).

11 Feig, C. *et al.* Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 20212-20217, doi:10.1073/pnas.1320318110 (2013).

12 Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. *J Exp Med* **211**, 1503-1523, doi:10.1084/jem.20140692 (2014).

13 Kraman, M. *et al.* Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. *Science* **330**, 827-830, doi:10.1126/science.1195300 (2010).

14 Henry, L. R. *et al.* Clinical implications of fibroblast activation protein in patients with colon cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **13**, 1736-1741, doi:10.1158/1078-0432.CCR-06-1746 (2007).

15 Ariga, N., Sato, E., Ohuchi, N., Nagura, H. & Ohtani, H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. *International journal of cancer* **95**, 67-72, doi:10.1002/1097-0215(20010120)95:1<67::aid-ijc1012>3.0.co;2-u (2001).

16 Strutz, F. *et al.* Identification and characterization of a fibroblast marker: FSP1. *J Cell Biol* **130**, 393-405 (1995).

17 Friedman, G. *et al.* Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome. *Nature Cancer* **1**, 692-708, doi:10.1038/s43018-020-0082-y (2020).

18 Mills, L. D. *et al.* Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. *The Journal of biological chemistry* **288**, 11786-11794, doi:10.1074/jbc.M112.438846 (2013).

19 Yu, B. *et al.* Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. *BMC Cell Biol* **14**, 17, doi:10.1186/1471-2121-14-17 (2013).

20 True, L. D. *et al.* CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. *Mod Pathol* **23**, 1346-1356, doi:10.1038/modpathol.2010.122 (2010).

21 Schliekelman, M. J. *et al.* Thy-1(+) Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. *Sci Rep* **7**, 6478, doi:10.1038/s41598-017-06922-5 (2017).

22 Dominguez, C. X. *et al.* Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15(+) Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy. *Cancer Discov* **10**, 232-253, doi:10.1158/2159-8290.CD-19-0644 (2020).

23 Purcell, J. W. *et al.* LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. *Cancer research* **78**, 4059-4072, doi:10.1158/0008-5472.CAN-18-0327 (2018).

24 Barrera, L. N. *et al.* Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. *Cancer research* **80**, 2861-2873, doi:10.1158/0008-5472.CAN-19-3534 (2020).

25 O'Connell, J. T. *et al.* VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. *Proc Natl Acad Sci U S A* **108**, 16002-16007, doi:10.1073/pnas.1109493108 (2011).

26   De Wever, O. *et al.* Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. *FASEB J* **18**, 1016-1018, doi:10.1096/fj.03-1110fje (2004).

27   Gocheva, V. *et al.* Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. *Proceedings of the National Academy of Sciences of the United States of America* **114**, E5625-E5634, doi:10.1073/pnas.1707054114 (2017).

28   Bartoschek, M. *et al.* Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. *Nature communications* **9**, 5150, doi:10.1038/s41467-018-07582-3 (2018).

29   Frings, O. *et al.* Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. *Am J Pathol* **182**, 2037-2047, doi:10.1016/j.ajpath.2013.02.018 (2013).

30   Chen, Z. *et al.* Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. *Nature communications* **11**, 5077, doi:10.1038/s41467-020-18916-5 (2020).

31   Kilvaer, T. K. *et al.* Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. *Sci Rep* **9**, 10163, doi:10.1038/s41598-019-46510-3 (2019).

32   Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. *Cancer Cell* **17**, 135-147, doi:10.1016/j.ccr.2009.12.041 (2010).

33   Raz, Y. *et al.* Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. *The Journal of experimental medicine* **215**, 3075-3093, doi:10.1084/jem.20180818 (2018).

34   Goetz, J. G. *et al.* Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. *Cell* **146**, 148-163, doi:10.1016/j.cell.2011.05.040 (2011).

35   Sloan, E. K. *et al.* Stromal cell expression of caveolin-1 predicts outcome in breast cancer. *The American journal of pathology* **174**, 2035-2043, doi:10.2353/ajpath.2009.080924 (2009).

36   Witkiewicz, A. K. *et al.* An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. *The American journal of pathology* **174**, 2023-2034, doi:10.2353/ajpath.2009.080873 (2009).

37   Zhu, H. F. *et al.* Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B. *Cancer biology & therapy* **20**, 967-978, doi:10.1080/15384047.2019.1591122 (2019).

38   Chen, H. *et al.* High Intratumoral Expression of Tetranectin Associates with Poor Prognosis of Patients with Gastric Cancer after Gastrectomy. *Journal of Cancer* **8**, 3623-3630, doi:10.7150/jca.19438 (2017).

39   Sun, J. *et al.* CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment. *Cancer Cell Int* **20**, 106, doi:10.1186/s12935-020-01183-1 (2020).

40   Maehira, H. *et al.* Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population. *Annals of surgical oncology* **26**, 4791-4804, doi:10.1245/s10434-019-07891-x (2019).

41   Yao, J. X. *et al.* Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma. *Front Oncol* **10**, 1181, doi:10.3389/fonc.2020.01181 (2020).

42   Hoshino, A. *et al.* Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. *Cancer research* **71**, 4769-4779, doi:10.1158/0008-5472.CAN-10-3228 (2011).

43   Neri, S. *et al.* Podoplanin-expressing cancer-associated fibroblasts lead and enhance the local invasion of cancer cells in lung adenocarcinoma. *International journal of cancer* **137**, 784-796, doi:10.1002/ijc.29464 (2015).

44   Dias, P. *et al.* Evaluation of desmin as a diagnostic and prognostic marker of childhood rhabdomyosarcomas and embryonal sarcomas. *British journal of cancer* **56**, 361-365, doi:10.1038/bjc.1987.203 (1987).

45   Bernard, V. *et al.* Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. *Clinical cancer research : an official journal of the American Association for Cancer Research* **25**, 2194-2205, doi:10.1158/1078-0432.CCR-18-1955 (2019).

46   Tian, C. *et al.* Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. *Proceedings of the National Academy of Sciences of the United States of America*, doi:10.1073/pnas.1908626116 (2019).

47   Zhang, K. *et al.* The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. *Nature cell biology* **15**, 677-687, doi:10.1038/ncb2743 (2013).

48   Corsa, C. A. *et al.* The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis. *Cell reports* **15**, 2510-2523, doi:10.1016/j.celrep.2016.05.033 (2016).

49   Levental, K. R. *et al.* Matrix crosslinking forces tumor progression by enhancing integrin signaling. *Cell* **139**, 891-906, doi:10.1016/j.cell.2009.10.027 (2009).

50   Torres, S. *et al.* LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival. *Clinical cancer research : an official journal of the American Association for Cancer Research* **21**, 4892-4902, doi:10.1158/1078-0432.CCR-14-3096 (2015).

51   Mok, S. C. *et al.* A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. *Cancer cell* **16**, 521-532, doi:10.1016/j.ccr.2009.10.018 (2009).

52   Leung, C. S. *et al.* Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. *Nature communications* **5**, 5092, doi:10.1038/ncomms6092 (2014).

53   Neuzillet, C. *et al.* Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. *The Journal of pathology* **248**, 51-65, doi:10.1002/path.5224 (2019).

54   Vaz, J., Ansari, D., Sasor, A. & Andersson, R. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer. *Pancreas* **44**, 1024-1035, doi:10.1097/MPA.0000000000000409 (2015).

55   Provenzano, P. P. *et al.* Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. *Cancer cell* **21**, 418-429, doi:10.1016/j.ccr.2012.01.007 (2012).

56   Dornhofer, N. *et al.* Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. *Cancer research* **66**, 5816-5827, doi:10.1158/0008-5472.CAN-06-0081 (2006).

57   Barry-Hamilton, V. *et al.* Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. *Nature medicine* **16**, 1009-1017, doi:10.1038/nm.2208 (2010).

58   Djurec, M. *et al.* Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. *Proceedings of the National Academy of Sciences of the United States of America* **115**, E1147-E1156, doi:10.1073/pnas.1717802115 (2018).

59   Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. *Cancer cell* **21**, 836-847, doi:10.1016/j.ccr.2012.04.024 (2012).

60   Cortot, A. B. *et al.* Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. *Cancer Res* **73**, 834-843, doi:10.1158/0008-5472.CAN-12-2066 (2013).

61   Haluska, P. *et al.* Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. *Clin Cancer Res* **20**, 4747-4757, doi:10.1158/1078-0432.CCR-14-0114 (2014).

62   Kakarla, S. *et al.* Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. *Mol Ther* **21**, 1611-1620, doi:10.1038/mt.2013.110 (2013).

63   Wang, L. C. *et al.* Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer Immunol Res* **2**, 154-166, doi:10.1158/2326-6066.CIR-13-0027 (2014).

64   Lo, A. *et al.* Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. *Cancer Res* **75**, 2800-2810, doi:10.1158/0008-5472.CAN-14-3041 (2015).

65   Scott, A. M. *et al.* A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* **9**, 1639-1647 (2003).

66   Klein, C. *et al.* Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer. *Blood* **122**, 2278-2278, doi:10.1182/blood.V122.21.2278.2278 (2013).

67   Carapuca, E. F. *et al.* Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. *The Journal of pathology* **239**, 286-296, doi:10.1002/path.4727 (2016).

68   Froeling, F. E. *et al.* Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. *Gastroenterology* **141**, 1486-1497, 1497 e1481-1414, doi:10.1053/j.gastro.2011.06.047 (2011).

69   Sherman, M. H. *et al.* Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. *Cell* **159**, 80-93, doi:10.1016/j.cell.2014.08.007 (2014).

70   Morris, J. C. *et al.* Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. *PloS one* **9**, e90353, doi:10.1371/journal.pone.0090353 (2014).

71   Melisi, D. *et al.* Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. *British journal of cancer* **119**, 1208-1214, doi:10.1038/s41416-018-0246-z (2018).

72   Catenacci, D. V. *et al.* Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. *J Clin Oncol* **33**, 4284-4292, doi:10.1200/JCO.2015.62.8719 (2015).

73   Mathew, E. *et al.* The transcription factor GLI1 modulates the inflammatory response during pancreatic tissue remodeling. *The Journal of biological chemistry* **289**, 27727-27743, doi:10.1074/jbc.M114.556563 (2014).

74   Olive, K. P. *et al.* Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. *Science* **324**, 1457-1461, doi:10.1126/science.1171362 (2009).

75   Tape, C. J. *et al.* Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. *Cell* **165**, 1818, doi:10.1016/j.cell.2016.05.079 (2016).

76   Bockorny, B. *et al.* BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. *Nature medicine* **26**, 878-885, doi:10.1038/s41591-020-0880-x (2020).

77   Konstantinidou, G. *et al.* RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. *Cancer Discov* **3**, 444-457, doi:10.1158/2159-8290.CD-12-0388 (2013).

78   Bahleda, R. *et al.* Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. *Clin Cancer Res* **25**, 4888-4897, doi:10.1158/1078-0432.CCR-18-3334 (2019).

79   Perera, T. P. S. *et al.* Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. *Mol Cancer Ther* **16**, 1010-1020, doi:10.1158/1535-7163.MCT-16-0589 (2017).

80   Pal, S. K. *et al.* Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. *Cancer Discov* **8**, 812-821, doi:10.1158/2159-8290.CD-18-0229 (2018).

81   Yap, T. A. *et al.* AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. *Clinical cancer research : an official journal of the American Association for Cancer Research* **18**, 3912-3923, doi:10.1158/1078-0432.CCR-11-3313 (2012).

82   Pietras, K., Pahler, J., Bergers, G. & Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. *PLoS Med* **5**, e19, doi:10.1371/journal.pmed.0050019 (2008).

83   Haubeiss, S. *et al.* Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. *Mol Cancer* **9**, 168, doi:10.1186/1476-4598-9-168 (2010).

84   Johnson, D. E., O'Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol* **15**, 234-248, doi:10.1038/nrclinonc.2018.8 (2018).

85   Hong, D. *et al.* AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Sci Transl Med* **7**, 314ra185, doi:10.1126/scitranslmed.aac5272 (2015).

86   Shah, M. A. *et al.* Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. *Clin Cancer Res* **24**, 3829-3837, doi:10.1158/1078-0432.CCR-17-2469 (2018).

87   Chiappori, A. A. *et al.* A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **13**, 2091-2099, doi:10.1158/1078-0432.CCR-06-1586 (2007).

88   Reardon, D. A. *et al.* Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. *J Clin Oncol* **24**, 115-122, doi:10.1200/JCO.2005.03.4082 (2006).